Week 06, 2018pdf, World Health Organization, SouthEast Asia Regional Office
Vol. 22, Week 06, 2018
Published 12 February 2018
Meetings/ Important events:
Regional Consultation on Human Papilloma Vaccine Introduction, New Delhi, India, 28-30 March 2018
Table 1: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2018* (data as of 12 February 2018)
Case classification (number)
Discarded non-measles nonrubella cases
Pending classification
93
Epidemiologicallyconfirmed
97
Reporting
% di s tri cts
ra te of
reporting a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
n
n
non-rubel l a
pop
pop
na tiona l
ca s es per
l evel per
n
100,000 pop
100,000 pop n
Laboratory-confirmed
100
Rubel l a
Clinically-confirmed
% s erol ogy
res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory
Mea s l es
Epidemiologicallyconfirmed
Number of
s erum
s peci mens
recei ved i n
l a bora tory
% s erum
s peci mens
recei ved a t
l a bora tory
w/i n 5
da ys of
col l ection
%
s peci mens
tes ted for
s erol ogy
of
s peci mens
recei ved
i n the
l a bora tory
Laboratory-confirmed
%
s us pected
ca s es wi th
%
Number of a dequa te s us pected
s us pected i nves tiga ti ca s es wi th
on
mea s l es
s erum
i ni tia ted s peci mens
ca s es
w/i n 48
col l ected
hours of
notifi ca tion
252
90
97
244
105
0
7
12
121
7
48
0.04
75
6.22
7.39
Bhutan
0
0
0
0
0
0
0
0
0
0
0
0.00
65
0.00
0.00
DPR Korea
0
0
0
0
0
0
0
0
0
0
0
0.00
0.00
0.00
1 192
0
41
461
272
0
0
8
49
863
4
0.59
1.86
0.39
2
0
100
0
0
0
0
0
0
2
0
0.01
2
50
100
2
0
0
0
0
0
2
0
5.07
Myanmar
8
100
88
7
100
0
0
0
0
0
0
0
8
0
0.13
14
0.00
0.00
Nepal
32
0
100
3
100
0
0
0
0
0
0
0
32
0
1.02
55
0.00
0.00
0
0
0
0
0
0
0
0
0.00
23
58
95
1
85
1
120
2
39
0.03
Countries
Bangladesh
India 3
Indonesia
4
Maldives
62
73
66
0
0
1
50
Sri Lanka
0
0
0
0
Thailand
304
32
86
232
80
37
97
95
35
100
74
74
0
0
0
0
25
12
68
8.58
1 829
20
59
984
77
85
70
472
1
92
21
315
928
159
0.05
Timor-Leste
SEAR
1
Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases
2
Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases
4
5
60
38
A lso includes the cases fro m enhanced measles case-based surveillance.
0.00
0.00
0.00
0.00
62.00
0.42
24.13
16.13
0.00
178.75
2.61
1.55
ND=No data
3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry
* Figures in the table 1 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.
Table 2: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2017* (data as of 12 February 2018)
Case classification (number)
6 577
100
79
166
59
DPR Korea
105
100
100
105
100
20 148
0
30
5 788
92
10 685
0
99
0
India 3
Indonesia
4
Pending classification
Discarded non-measles nonrubella cases
Epidemiologicallyconfirmed
80
84
Reporting
% di s tri cts
ra te of
reporting a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
n
non-rubel l a
pop
pop n
na tiona l
ca s es per
l evel per
100,000 pop n
100,000 pop n
Laboratory-confirmed
92
221
Rubel l a
Clinically-confirmed
100
8 218
Bhutan
% s erol ogy
res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory
Mea s l es
Epidemiologicallyconfirmed
Bangladesh
Number of
s erum
s peci mens
recei ved i n
l a bora tory
% s erum
s peci mens
recei ved a t
l a bora tory
w/i n 5
da ys of
col l ection
%
s peci mens
tes ted for
s erol ogy
of
s peci mens
recei ved
i n the
l a bora tory
Laboratory-confirmed
Countries
%
s us pected
%
ca s es wi th
Number of a dequa te s us pected
s us pected i nves tiga ti ca s es wi th
s erum
on
mea s l es
i ni tia ted s peci mens
ca s es
col l ected
w/i n 48
hours of
notifi ca tion
64
2 709
961
512
240
58
3 738
0
2.40
80
26.81
46
14
0
0
2
0
160
45
21.47
55
18.79
2.68
100
99
0
0
0
0
0
105
0
0.42
0.00
0.00
97
66
3 240
5 803
0
745
1 998
2 695
5 667
0.21
0
0
0
0
0
0
10 685
0.00
3
1.91
7.15
2.17
0.00
0.00
2.93
Maldives
66
97
100
66
100
100
71
1
0
0
1
0
59
5
17.26
15
2.93
Myanmar
1 731
40
88
1 526
99
100
94
1 019
205
74
4
0
424
5
0.82
11
25.24
0.08
1 031
21
91
514
66
73
65
24
11
21
0
826
84
3.02
56
3.66
0.77
27
62.00
0.42
Nepal
5
Sri Lanka
242
98
89
212
92
100
64
1
0
22
2
0
217
0
1.05
Thailand
2 989
28
86
2 449
58
95
58
1 453
16
546
24
0
857
93
1.32
145
100
99
137
100
74
57
0
0
0
9
0
130
6
10.73
45 581
22
63
17 540
90
100
67
8 502
7 009
1 165
1 048
2 056
9 211
16 590
0.49
Timor-Leste
SEAR
1
Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases
4
A lso includes the cases fro m enhanced measles case-based surveillance.
2
Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases
5
So me Lab data variables no t available.
46
31.06
0.37
0.00
7.43
8.94
1.66
ND=No data
3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry
* Figures in the table 2 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.
Data Sources: Ministries of Health in SEAR Countries.
Published by Immunization & Vaccine Development, World Health Organization, Regional Office for South-East Asia, New Delhi – 110002, India
Tel: 91-11-2337-0804 / 91-11-4304-0000 Fax: 91-11-2337-0251 / 0106 E-mail: SearEpidata@who.int, URL:
http://www.searo.who.int/topics/immunization/
Vol. 22,
Week 06, 2018
Vaccine Preventable Disease Surveillance Bulletin
Page 2
Table 3: Classification of AFP Cases and Key Surveillance Indicators, 2017-2018 (data as of 12 February 2018)
2017 (Onset)
2018 (Onset)
AFP
Surveillance Indicators
Case Classification 1
AFP Rate
Non-Polio AFP Rate
% with any specimen
AFP Cases
Compatible
Discarded (Non-polio
AFP)
Total
>90 Days 3
AFP Rate
Non-Polio AFP Rate
% with 2 spec., at least
24 hrs apart, w/in 14
days
% with any specimen
1 351
17
16
2.75
2.71
98
99
74
0
0
0
32
42
0
1.29
0.56
100
100
7
2
1
3.64
2.83
89
100
0
0
0
0
0
0
0
0.00
0.00
0
0
104
0
0
0
75
29
27
1.82
1.31
97
100
0
0
0
0
0
0
0
0.00
0.00
0
0
4
Vaccine Derived
Poliovirus Cases
Vaccine Derived
Poliovirus Cases
Wild Poliovirus Cases
>90 Days 3
0
0
Pending
% with 2 spec., at least
24 hrs apart, w/in 14
days
Total
0
0
4
0
0
Wild Poliovirus Cases
Discarded (Non-polio
AFP)
Specim en
Compatible
DPR Korea
Case Classification 1
Specim en
9
AFP Cases
Bangladesh
2
Surveillance Indicators
Annualized
AFP Rates 2
1 368
Country
Bhutan
AFP Rates
AFP
India
39 287
0
0
14
37 432 1 841 1 126
8.96
8.54
86
98
2 273
0
0
0
Indonesia
1 614
0
0
1
1 411
2.30
2.01
83
97
33
0
0
0
202
162
Pending
1 165 1 108
16
17
0
4.49
2.30
87
96
0
0.41
0.20
97
100
Maldives
6
0
0
0
5
1
0
6.34
5.29
67
100
0
0
0
0
0
0
0
0.00
0.00
0
0
Myanm ar
394
0
0
0
376
18
1
2.92
2.79
95
100
21
0
0
0
0
21
0
1.35
0.00
100
100
Nepal
364
0
0
0
360
4
3
4.20
4.15
98
100
19
0
0
0
12
7
0
1.90
1.20
100
100
Sri Lanka
70
0
0
0
69
1
1
1.29
1.27
84
100
5
0
0
0
3
2
0
0.80
0.48
80
100
Thailand
187
0
0
0
131
56
36
1.62
1.13
67
92
2
0
0
0
0
2
0
0.15
0.00
100
100
3
0
0
0
1
2
1
0.65
0.22
33
100
0
0
0
0
0
0
0
0.00
0.00
0
0
43 406
0
0
15
7.18
6.82
86
98
2 427
0
0
0
0
3.48
1.76
88
96
Tim or-Leste
SEAR
41 218 2 173 1 374
1 228 1 199
1
All countries are using the virologic classification scheme.
2
AFP rates per 100,000 children aged 15 years of age or missing age information are excluded).
3
90 days calculation based on date of paralysis onset subtracted from date of last report received from member countries by SEARO.
Table 4: Intratypic Differentiation (ITD) of Isolates from AFP Cases, 2017-2018 (data as of 12 February 2018)
0
0
7
5
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
DPR Korea
NPL, Pyongyong
India
0
0
0
0
0
2
0
0
0
0
0
0
0
Vaccine
mixture
NPEV by
PCR
0
7
Days days
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
BJMC, Ahmedabad
232
0
78
0
0
0
0
67
78
9
0
0
0
0
3
0
0
0
0
0
0
1
0
0
0
0
2
NIV, Bengaluru
152
0
57
0
0
0
0
35
45
15
0
0
0
0
1
0
0
0
0
0
0
1
0
0
0
0
0
0
ERC, Mumbai
155
0
51
0
0
0
0
47
36
21
0
0
0
0
2
0
1
0
0
0
0
0
0
0
0
0
1
0
0
2
0
0
0
0
0
3
1
0
0
1
0
SGPGI, Lucknow
286
0
57
0
0
0
0
100
63
25
41
0
0
0
7
KIPM, Chennai
50
0
10
0
0
0
0
26
14
0
0
0
0
0
0
NCDC, Delhi
205
0
58
0
0
0
0
89
50
8
0
0
0
0
4
0
1
0
0
0
0
0
1
0
0
0
2
0
IoS, Kolkatta
174
0
55
0
0
0
0
39
58
18
3
0
0
1
4
0
0
0
0
0
0
2
2
0
0
0
0
0
CRI, Kasauli
22
0
11
0
0
0
0
6
5
0
0
0
0
0
0
1 276
0
377
0
0
0
0
409
349
96
44
0
0
1
21
0
4
0
0
0
0
4
6
1
0
0
6
0
India Total
Indonesia
Negative
0
0
NEV
0
0
Vaccine
8
0
Wild
0
0
VDPV
20
Wild
IPH, Dhaka
NIH, Bangkok
Vaccine
Bangladesh
Bhutan
Results
pending
Vaccine
7
Days days
Intratypic Differentiation results
Polio 1
Polio 2
Polio 3
Wild
Results
pending
AFP cases
referred
for ITD
NEV
Negative
2018
Vaccine
mixture
NPEV by
PCR
Wild
Vaccine
VDPV
Vaccine
Wild
Vaccine
ITD Labs
Wild
Country of
Case
AFP cases
referred
for ITD
2017
Intratypic Differentiation results
Polio 1
Polio 2
Polio 3
Bio Farma, Bandung
2
0
0
0
0
0
0
2
0
0
0
0
0
0
0
NIHRD, Jakarta
2
0
0
0
0
0
0
0
2
0
0
0
0
0
0
PHL, Surabaya
1
0
0
0
0
0
0
1
0
0
0
0
0
0
1
0
0
0
0
0
0
0
1
0
0
0
0
0
Indonesia Total
5
0
0
0
0
0
0
3
2
0
0
0
0
0
1
0
0
0
0
0
0
0
1
0
0
0
0
0
Myanmar
NHL, Yangon
6
0
1
0
0
0
0
4
1
0
0
0
0
0
0
Nepal
NIH, Bangkok
5
0
0
0
0
0
0
3
2
0
0
0
0
0
0
Sri Lanka
MRI, Colombo
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Thailand
NIH, Bangkok
0
4
0
0
0
0
6
7
1
0
0
6
0
TOTAL
5
0
2
0
0
0
0
3
0
0
0
0
0
0
0
1 317
0
388
0
0
0
0
429
359
96
44
0
0
1
24
Published 12 February 2018
Meetings/ Important events:
Regional Consultation on Human Papilloma Vaccine Introduction, New Delhi, India, 28-30 March 2018
Table 1: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2018* (data as of 12 February 2018)
Case classification (number)
Discarded non-measles nonrubella cases
Pending classification
93
Epidemiologicallyconfirmed
97
Reporting
% di s tri cts
ra te of
reporting a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
n
n
non-rubel l a
pop
pop
na tiona l
ca s es per
l evel per
n
100,000 pop
100,000 pop n
Laboratory-confirmed
100
Rubel l a
Clinically-confirmed
% s erol ogy
res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory
Mea s l es
Epidemiologicallyconfirmed
Number of
s erum
s peci mens
recei ved i n
l a bora tory
% s erum
s peci mens
recei ved a t
l a bora tory
w/i n 5
da ys of
col l ection
%
s peci mens
tes ted for
s erol ogy
of
s peci mens
recei ved
i n the
l a bora tory
Laboratory-confirmed
%
s us pected
ca s es wi th
%
Number of a dequa te s us pected
s us pected i nves tiga ti ca s es wi th
on
mea s l es
s erum
i ni tia ted s peci mens
ca s es
w/i n 48
col l ected
hours of
notifi ca tion
252
90
97
244
105
0
7
12
121
7
48
0.04
75
6.22
7.39
Bhutan
0
0
0
0
0
0
0
0
0
0
0
0.00
65
0.00
0.00
DPR Korea
0
0
0
0
0
0
0
0
0
0
0
0.00
0.00
0.00
1 192
0
41
461
272
0
0
8
49
863
4
0.59
1.86
0.39
2
0
100
0
0
0
0
0
0
2
0
0.01
2
50
100
2
0
0
0
0
0
2
0
5.07
Myanmar
8
100
88
7
100
0
0
0
0
0
0
0
8
0
0.13
14
0.00
0.00
Nepal
32
0
100
3
100
0
0
0
0
0
0
0
32
0
1.02
55
0.00
0.00
0
0
0
0
0
0
0
0
0.00
23
58
95
1
85
1
120
2
39
0.03
Countries
Bangladesh
India 3
Indonesia
4
Maldives
62
73
66
0
0
1
50
Sri Lanka
0
0
0
0
Thailand
304
32
86
232
80
37
97
95
35
100
74
74
0
0
0
0
25
12
68
8.58
1 829
20
59
984
77
85
70
472
1
92
21
315
928
159
0.05
Timor-Leste
SEAR
1
Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases
2
Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases
4
5
60
38
A lso includes the cases fro m enhanced measles case-based surveillance.
0.00
0.00
0.00
0.00
62.00
0.42
24.13
16.13
0.00
178.75
2.61
1.55
ND=No data
3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry
* Figures in the table 1 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.
Table 2: Measles & Rubella Laboratory Supported Case-based Surveillance Performance Indicators by Country, 2017* (data as of 12 February 2018)
Case classification (number)
6 577
100
79
166
59
DPR Korea
105
100
100
105
100
20 148
0
30
5 788
92
10 685
0
99
0
India 3
Indonesia
4
Pending classification
Discarded non-measles nonrubella cases
Epidemiologicallyconfirmed
80
84
Reporting
% di s tri cts
ra te of
reporting a t
di s ca rded
Mea s l es
Rubel l a
l ea s t
non2 di s ca rded i nci dence 1 i nci dence 2
mea s l es
nonper
per
non-rubel l a
mea s l es
mi l l i on
mi l l i on
ca s es a t the
n
non-rubel l a
pop
pop n
na tiona l
ca s es per
l evel per
100,000 pop n
100,000 pop n
Laboratory-confirmed
92
221
Rubel l a
Clinically-confirmed
100
8 218
Bhutan
% s erol ogy
res ul ts
reported
w/i n 4 da ys
of
s peci men
recei ved a t
l a bora tory
Mea s l es
Epidemiologicallyconfirmed
Bangladesh
Number of
s erum
s peci mens
recei ved i n
l a bora tory
% s erum
s peci mens
recei ved a t
l a bora tory
w/i n 5
da ys of
col l ection
%
s peci mens
tes ted for
s erol ogy
of
s peci mens
recei ved
i n the
l a bora tory
Laboratory-confirmed
Countries
%
s us pected
%
ca s es wi th
Number of a dequa te s us pected
s us pected i nves tiga ti ca s es wi th
s erum
on
mea s l es
i ni tia ted s peci mens
ca s es
col l ected
w/i n 48
hours of
notifi ca tion
64
2 709
961
512
240
58
3 738
0
2.40
80
26.81
46
14
0
0
2
0
160
45
21.47
55
18.79
2.68
100
99
0
0
0
0
0
105
0
0.42
0.00
0.00
97
66
3 240
5 803
0
745
1 998
2 695
5 667
0.21
0
0
0
0
0
0
10 685
0.00
3
1.91
7.15
2.17
0.00
0.00
2.93
Maldives
66
97
100
66
100
100
71
1
0
0
1
0
59
5
17.26
15
2.93
Myanmar
1 731
40
88
1 526
99
100
94
1 019
205
74
4
0
424
5
0.82
11
25.24
0.08
1 031
21
91
514
66
73
65
24
11
21
0
826
84
3.02
56
3.66
0.77
27
62.00
0.42
Nepal
5
Sri Lanka
242
98
89
212
92
100
64
1
0
22
2
0
217
0
1.05
Thailand
2 989
28
86
2 449
58
95
58
1 453
16
546
24
0
857
93
1.32
145
100
99
137
100
74
57
0
0
0
9
0
130
6
10.73
45 581
22
63
17 540
90
100
67
8 502
7 009
1 165
1 048
2 056
9 211
16 590
0.49
Timor-Leste
SEAR
1
Includes labo rato ry-co nfirmed, epidemio lo gically-linked and clinically-co nfirmed measles cases
4
A lso includes the cases fro m enhanced measles case-based surveillance.
2
Includes labo rato ry-co nfirmed and epidemio lo gically-linked rubella cases
5
So me Lab data variables no t available.
46
31.06
0.37
0.00
7.43
8.94
1.66
ND=No data
3 Cases fro m suspected measles o utbreak investigatio n o nly, case based surveillance is gradually exCA nding in the co untry
* Figures in the table 2 are restricted to availability of various dates required for calculation. Thus they may not adequately reflect cases with missing dates for various timelines.
Data Sources: Ministries of Health in SEAR Countries.
Published by Immunization & Vaccine Development, World Health Organization, Regional Office for South-East Asia, New Delhi – 110002, India
Tel: 91-11-2337-0804 / 91-11-4304-0000 Fax: 91-11-2337-0251 / 0106 E-mail: SearEpidata@who.int, URL:
http://www.searo.who.int/topics/immunization/
Vol. 22,
Week 06, 2018
Vaccine Preventable Disease Surveillance Bulletin
Page 2
Table 3: Classification of AFP Cases and Key Surveillance Indicators, 2017-2018 (data as of 12 February 2018)
2017 (Onset)
2018 (Onset)
AFP
Surveillance Indicators
Case Classification 1
AFP Rate
Non-Polio AFP Rate
% with any specimen
AFP Cases
Compatible
Discarded (Non-polio
AFP)
Total
>90 Days 3
AFP Rate
Non-Polio AFP Rate
% with 2 spec., at least
24 hrs apart, w/in 14
days
% with any specimen
1 351
17
16
2.75
2.71
98
99
74
0
0
0
32
42
0
1.29
0.56
100
100
7
2
1
3.64
2.83
89
100
0
0
0
0
0
0
0
0.00
0.00
0
0
104
0
0
0
75
29
27
1.82
1.31
97
100
0
0
0
0
0
0
0
0.00
0.00
0
0
4
Vaccine Derived
Poliovirus Cases
Vaccine Derived
Poliovirus Cases
Wild Poliovirus Cases
>90 Days 3
0
0
Pending
% with 2 spec., at least
24 hrs apart, w/in 14
days
Total
0
0
4
0
0
Wild Poliovirus Cases
Discarded (Non-polio
AFP)
Specim en
Compatible
DPR Korea
Case Classification 1
Specim en
9
AFP Cases
Bangladesh
2
Surveillance Indicators
Annualized
AFP Rates 2
1 368
Country
Bhutan
AFP Rates
AFP
India
39 287
0
0
14
37 432 1 841 1 126
8.96
8.54
86
98
2 273
0
0
0
Indonesia
1 614
0
0
1
1 411
2.30
2.01
83
97
33
0
0
0
202
162
Pending
1 165 1 108
16
17
0
4.49
2.30
87
96
0
0.41
0.20
97
100
Maldives
6
0
0
0
5
1
0
6.34
5.29
67
100
0
0
0
0
0
0
0
0.00
0.00
0
0
Myanm ar
394
0
0
0
376
18
1
2.92
2.79
95
100
21
0
0
0
0
21
0
1.35
0.00
100
100
Nepal
364
0
0
0
360
4
3
4.20
4.15
98
100
19
0
0
0
12
7
0
1.90
1.20
100
100
Sri Lanka
70
0
0
0
69
1
1
1.29
1.27
84
100
5
0
0
0
3
2
0
0.80
0.48
80
100
Thailand
187
0
0
0
131
56
36
1.62
1.13
67
92
2
0
0
0
0
2
0
0.15
0.00
100
100
3
0
0
0
1
2
1
0.65
0.22
33
100
0
0
0
0
0
0
0
0.00
0.00
0
0
43 406
0
0
15
7.18
6.82
86
98
2 427
0
0
0
0
3.48
1.76
88
96
Tim or-Leste
SEAR
41 218 2 173 1 374
1 228 1 199
1
All countries are using the virologic classification scheme.
2
AFP rates per 100,000 children aged 15 years of age or missing age information are excluded).
3
90 days calculation based on date of paralysis onset subtracted from date of last report received from member countries by SEARO.
Table 4: Intratypic Differentiation (ITD) of Isolates from AFP Cases, 2017-2018 (data as of 12 February 2018)
0
0
7
5
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
0
0
DPR Korea
NPL, Pyongyong
India
0
0
0
0
0
2
0
0
0
0
0
0
0
Vaccine
mixture
NPEV by
PCR
0
7
Days days
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
BJMC, Ahmedabad
232
0
78
0
0
0
0
67
78
9
0
0
0
0
3
0
0
0
0
0
0
1
0
0
0
0
2
NIV, Bengaluru
152
0
57
0
0
0
0
35
45
15
0
0
0
0
1
0
0
0
0
0
0
1
0
0
0
0
0
0
ERC, Mumbai
155
0
51
0
0
0
0
47
36
21
0
0
0
0
2
0
1
0
0
0
0
0
0
0
0
0
1
0
0
2
0
0
0
0
0
3
1
0
0
1
0
SGPGI, Lucknow
286
0
57
0
0
0
0
100
63
25
41
0
0
0
7
KIPM, Chennai
50
0
10
0
0
0
0
26
14
0
0
0
0
0
0
NCDC, Delhi
205
0
58
0
0
0
0
89
50
8
0
0
0
0
4
0
1
0
0
0
0
0
1
0
0
0
2
0
IoS, Kolkatta
174
0
55
0
0
0
0
39
58
18
3
0
0
1
4
0
0
0
0
0
0
2
2
0
0
0
0
0
CRI, Kasauli
22
0
11
0
0
0
0
6
5
0
0
0
0
0
0
1 276
0
377
0
0
0
0
409
349
96
44
0
0
1
21
0
4
0
0
0
0
4
6
1
0
0
6
0
India Total
Indonesia
Negative
0
0
NEV
0
0
Vaccine
8
0
Wild
0
0
VDPV
20
Wild
IPH, Dhaka
NIH, Bangkok
Vaccine
Bangladesh
Bhutan
Results
pending
Vaccine
7
Days days
Intratypic Differentiation results
Polio 1
Polio 2
Polio 3
Wild
Results
pending
AFP cases
referred
for ITD
NEV
Negative
2018
Vaccine
mixture
NPEV by
PCR
Wild
Vaccine
VDPV
Vaccine
Wild
Vaccine
ITD Labs
Wild
Country of
Case
AFP cases
referred
for ITD
2017
Intratypic Differentiation results
Polio 1
Polio 2
Polio 3
Bio Farma, Bandung
2
0
0
0
0
0
0
2
0
0
0
0
0
0
0
NIHRD, Jakarta
2
0
0
0
0
0
0
0
2
0
0
0
0
0
0
PHL, Surabaya
1
0
0
0
0
0
0
1
0
0
0
0
0
0
1
0
0
0
0
0
0
0
1
0
0
0
0
0
Indonesia Total
5
0
0
0
0
0
0
3
2
0
0
0
0
0
1
0
0
0
0
0
0
0
1
0
0
0
0
0
Myanmar
NHL, Yangon
6
0
1
0
0
0
0
4
1
0
0
0
0
0
0
Nepal
NIH, Bangkok
5
0
0
0
0
0
0
3
2
0
0
0
0
0
0
Sri Lanka
MRI, Colombo
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Thailand
NIH, Bangkok
0
4
0
0
0
0
6
7
1
0
0
6
0
TOTAL
5
0
2
0
0
0
0
3
0
0
0
0
0
0
0
1 317
0
388
0
0
0
0
429
359
96
44
0
0
1
24